SLC5A2 and type 2 diabetes mellitus: Sodium glucose transporter-2 inhibitors (SGLT-2i) were initially designed as antidiabetic drugs for patients with T2D, acting on the sodium/glucose cotransporter 2 protein expressed in the renal proximal convoluted tubules of the nephron, leading to a reduction in the reabsorption of filtered glucose and thus, improving glycemic control [171,172].